PRLD Company Profile and Key Details

Q: Who are the executives of PRLD?

Dr. Edna Huang M.D.Pres & Chief Medical OfficerDr. Peggy A. Scherle Ph.D.Chief Scientific OfficerDr. Neelesh Sharma M.D., Ph.D.Senior Vice President of Clinical Devel.Dr. Krishna Vaddi D.V.M., Ph.D.Founder, Chief Executive Officer & DirectorMs. Aimee Crombie Ph.D.Senior Vice President and Head of Strategic Planning & OperationsDr. Madhu Pudipeddi Ph.D.Senior Vice President of Technical OperationsMr. Naveen Babbar Ph.D.Senior Vice President of Translation MedicineMr. Bryant David LimChief Legal Officer & Corporation Sec.Ms. Michele Porreca M.B.A.Chief People OfficerLindsey TrickettVice President of Investor RelationsMr. Bryant David Lim J.D.Chief Legal Officer & Corporation Sec.Dr. Andrew P. Combs Ph.D.Executive Vice President & Head of Chemistry

NASDAQ : PRLD

Prelude Therapeutics

$4.59

At Close 4:00 PM

65.46

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Prelude Therapeutics Incorporated (PRLD) stock remained unchanged at $4.59 a share on NASDAQ. The stock opened at $4.60, fluctuating between $4.50 to $4.68 during the session.

Stock Snapshot

4.59

Prev. Close

261.32M

Market Cap

4.5

Day Low

-4.59

P/E Ratio

-1

EPS (TTM)

-2.01

Cash Flow per Share

4.6

Open

78.5M

Number of Shares

4.68

Day High

55.81%

Free Float in %

4.32

Book Value

274.55K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 14, 2026	4.60	4.68	4.50	4.59	274.55K
Sep 11, 2026	4.72	4.75	4.56	4.59	520.34K
Sep 10, 2026	5.04	5.22	4.64	4.67	561.92K
Sep 09, 2026	5.25	5.34	5.06	5.09	311.89K
Sep 08, 2026	5.38	5.46	5.19	5.30	257.58K
Sep 04, 2026	5.19	5.52	5.19	5.46	400.28K
Sep 03, 2026	5.44	5.62	5.11	5.25	577.96K
Sep 02, 2026	5.53	5.82	5.30	5.43	355.07K
Sep 01, 2026	5.55	5.61	5.25	5.49	538.44K
Aug 31, 2026	5.39	5.63	5.24	5.60	737.63K
Aug 28, 2026	6.27	6.38	5.42	5.47	725K
Aug 27, 2026	6.48	6.61	6.21	6.34	364.36K
Aug 26, 2026	6.61	6.71	6.37	6.56	463.18K
Aug 25, 2026	6.57	6.70	6.31	6.59	415.43K
Aug 24, 2026	6.64	6.83	6.12	6.47	515.66K
Aug 21, 2026	6.56	6.82	6.40	6.63	513.09K
Aug 20, 2026	5.70	6.65	5.70	6.50	2.43M
Aug 19, 2026	5.84	5.90	5.66	5.78	421.04K
Aug 18, 2026	5.62	5.78	5.49	5.75	268.37K
Aug 17, 2026	5.57	5.86	5.45	5.63	265.3K

Contact Details

Wilmington, DE 19805

United States

https://www.preludetx.com 302 467 1280

About Company

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

Stock Peers

ARGX

6.15+0.62%

argenx SE$990.54 REGN

12.25+1.57%

Regeneron Pharmaceuticals, Inc.$793.74 MDGL

5.57+1.04%

Madrigal Pharmaceuticals, Inc.$540.06 VRTX

4.07+0.79%

Vertex Pharmaceuticals Incorporated$519.51 UTHR

5.59+1.12%

United Therapeutics Corporation$502.70 ONC

7.32+2.11%

BeOne Medicines AG$353.83 KRYS

-6.97-2.01%

Krystal Biotech, Inc.$340.03 PRAX

-4.03-1.20%

Praxis Precision Medicines, Inc.$330.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-3.82-1.34%

Ligand Pharmaceuticals Incorporated$280.65

Frequently Asked Questions

What is the current Prelude Therapeutics Incorporated (PRLD) stock price?

Prelude Therapeutics Incorporated (NASDAQ: PRLD) stock price is $4.59 in the last trading session. During the trading session, PRLD stock reached the peak price of $4.68 while $4.50 was the lowest point it dropped to. The percentage change in PRLD stock occurred in the recent session was 0% while the dollar amount for the price change in PRLD stock was $0.00.

PRLD's industry and sector of operation?

The NASDAQ listed PRLD is part of Biotechnology industry that operates in the broader Healthcare sector. Prelude Therapeutics Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PRLD?

Dr. Edna Huang M.D.
Pres & Chief Medical Officer
Dr. Peggy A. Scherle Ph.D.
Chief Scientific Officer
Dr. Neelesh Sharma M.D., Ph.D.
Senior Vice President of Clinical Devel.
Dr. Krishna Vaddi D.V.M., Ph.D.
Founder, Chief Executive Officer & Director
Ms. Aimee Crombie Ph.D.
Senior Vice President and Head of Strategic Planning & Operations
Dr. Madhu Pudipeddi Ph.D.
Senior Vice President of Technical Operations
Mr. Naveen Babbar Ph.D.
Senior Vice President of Translation Medicine
Mr. Bryant David Lim
Chief Legal Officer & Corporation Sec.
Ms. Michele Porreca M.B.A.
Chief People Officer
Lindsey Trickett
Vice President of Investor Relations
Mr. Bryant David Lim J.D.
Chief Legal Officer & Corporation Sec.
Dr. Andrew P. Combs Ph.D.
Executive Vice President & Head of Chemistry

How PRLD did perform over past 52-week?

PRLD's closing price is 367.89% higher than its 52-week low of $0.98 where as its distance from 52-week high of $6.83 is -32.8%.

How many employees does PRLD have?

Number of PRLD employees currently stands at 79.

Link for PRLD official website?

Official Website of PRLD is: https://www.preludetx.com

How do I contact PRLD?

PRLD could be contacted at phone 302 467 1280 and can also be accessed through its website. PRLD operates from 175 Innovation Boulevard, Wilmington, DE 19805, United States.

How many shares of PRLD are traded daily?

PRLD stock volume for the day was 274.55K shares. The average number of PRLD shares traded daily for last 3 months was 506.92K.

What is the market cap of PRLD currently?

The market value of PRLD currently stands at $261.32M with its latest stock price at $4.59 and 78.5M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	79
Beta	0.96
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	79
Beta	0.96
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PRLD Company Profile and Key Details

Prelude Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways